Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma

Fig. 2

AHSA1 is a high-risk MM marker and induces proteasome inhibitor resistance in vitro and in vivo. A Box plot representing AHSA1 expression in eight MM risk subgroups from TT2 patient cohort. B IHC staining of AHSA1 and Ki67 expressions in MM patient samples. C AHSA1 mRNA expression in paired patient MM samples collected at first diagnosis and relapse stage. D IHC staining of AHSA1 expression in the relapsed samples and the corresponding samples from first diagnosis. E-F Elevated AHSA1 expression was correlated with decreased OS in relapsed patients from the (E) TT2 and (F) APEX cohorts by long-term following up. G Effects of Bortezomib on cell viability of H929 cells with or without overexpression of AHSA1. H IC50 values of BTZ, CZ and ADR in MM cells with or without overexpression of AHSA1. I The rate of BTZ-induced apoptosis was shown in the histogram. J Effects of BTZ on cell apoptosis in ARP1 cells with or without overexpression of AHSA1. K Effects of Bufalin on cell viability in ANBL6 DR (Bortezomib-resistant) cells. L Effects of Bufalin (60nM) on the cell viability of flow MRD-positive peripheral cells from first diagnosed and relapsed MM patients. M Time course of tumor growth in ARP1 AHSA1 WT/OE xenografts taken from NOD-SCID mice treated with vehicle, BTZ, or ADR. The data are expressed as mean ± SD.*p<0.05, **p<0.01, ***p<0.001

Back to article page